Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1531 to 1545 of 2188 results for guidelines

  1. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

  2. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

  3. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.

  4. Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (TA1099)

    Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.

  5. The PediGuard for placing pedicle screws in spinal surgery (MIB26)

    NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery

  6. OrganOx metra for liver transplant (MIB275)

    NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .

  7. Balloon cryoablation for Barrett's oesophagus (HTG767)

    Evidence-based recommendations on balloon cryoablation for Barrett's oesophagus. This involves freezing and destroying the abnormal cells using a balloon inflated with very cold gas.

  8. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  9. Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

    Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

  10. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

  11. OxyMask for delivering oxygen therapy (MIB160)

    NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .

  12. Weight management before, during and after pregnancy (PH27)

    The recommendations in this guideline on weight management during pregnancy have been updated and replaced by NICE's guideline on maternal and child nutrition (NG247). The recommendations on weight management before and after pregnancy have been updated and replaced by NICE’s guideline on overweight and obesity management (NG246).

  13. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  14. QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography (HTG571)

    Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.

  15. What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?

    results from a new economic model developed specifically for the cannabis guideline. The model included data from all relevant trials,...